Literature DB >> 19933805

Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Christian Joukhadar1, Satish Pillai, Christine Wennersten, Robert C Moellering, George M Eliopoulos.   

Abstract

With the current high prevalence of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) strains but in light of the general belief that beta-lactam antibiotics are more effective than vancomycin against infections caused by methicillin-susceptible S. aureus (MSSA) isolates, clinicians may utilize antistaphylococcal penicillins in combination with vancomycin for the empirical treatment of S. aureus infections. Vancomycin is considered to kill MSSA more slowly than oxacillin. Thus, we sought to evaluate the interaction of the combination of oxacillin and vancomycin on bacterial killing in vitro. Ten clinical isolates of MSSA isolated in the year 2000 were investigated. The killing observed at 24 h by vancomycin at 20 microg/ml, oxacillin at 16 microg/ml, or the combination did not differ (approximately 2.5 to 3.5 log10 CFU/ml). In a separate experiment, we assessed bacterial killing in a dynamic model simulating the free plasma concentration profiles expected following the administration of a combination of vancomycin at 1 g every 12 h and oxacillin at 1 g every 6 h. The time-kill profiles of these regimens against S. aureus ATCC 29213 were comparable to those observed in the fixed-concentration experiments. Using these methods, we found no evidence that vancomycin antagonized the bactericidal effect of oxacillin or that there was any benefit from use of the combination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933805      PMCID: PMC2812142          DOI: 10.1128/AAC.00348-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

Authors:  B E Domaracki; A M Evans; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

Authors:  J Blaser
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

3.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease.

Authors:  J Ruedy
Journal:  Can Med Assoc J       Date:  1966-02-05       Impact factor: 8.262

5.  Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.

Authors:  Julie A Wu; Caroline Kusuma; James J Mond; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

7.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

8.  Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.

Authors:  J R Cohn; D L Jungkind; J S Baker
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

10.  Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.

Authors:  L Cantoni; M P Glauser; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

View more
  6 in total

1.  Activity of oxacillin versus that of vancomycin against oxacillin-susceptible mecA-positive Staphylococcus aureus clinical isolates evaluated by population analyses, time-kill assays, and a murine thigh infection model.

Authors:  Maria Labrou; George Michail; Eleni Ntokou; Theodore E Pittaras; Spyros Pournaras; Athanassios Tsakris
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Sara E Cosgrove; George Sakoulas; Eli N Perencevich
Journal:  BMC Infect Dis       Date:  2011-10-19       Impact factor: 3.090

3.  Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?

Authors:  Yamuna Devi Bakthavatchalam; Ravikar Ralph; Balaji Veeraraghavan; Priyanka Babu; Elakkiya Munusamy
Journal:  Infect Dis Ther       Date:  2018-11-21

4.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279

5.  Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study.

Authors:  Davie Wong; Titus Wong; Marc Romney; Victor Leung
Journal:  BMC Infect Dis       Date:  2016-05-23       Impact factor: 3.090

Review 6.  Proximate and ultimate causes of the bactericidal action of antibiotics.

Authors:  Fernando Baquero; Bruce R Levin
Journal:  Nat Rev Microbiol       Date:  2020-10-06       Impact factor: 60.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.